Literature DB >> 22162506

Lack of investment in regulatory science is part of "innovation gap," believes FDA commissioner.

Elizabeth Sukkar.   

Abstract

Mesh：

Year:  2011        PMID： 22162506     DOI： 10.1136/bmj.d8017

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I--a method of manual documentary analysis.

Authors:  Nina Ilic; Snezana Savic; Evan Siegel; Kerry Atkinson; Ljiljana Tasic
Journal:  Stem Cells Transl Med       Date:  2012-12-04       Impact factor: 6.940
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.